Archive for the ‘MassBio’ Category

2017 MassBio Annual Meeting  March 30, 2017 8:00 AM – March 31, 2017 4:00 PM, Royal Sonesta Boston, Cambridge MA

Reporter: Aviva Lev-Ari, PhD, RN

 Leaders in Pharmaceutical Business Intelligence will cover the event

Aviva Lev-Ari, PhD, RN

will be streaming content using Social Media from the Royal Sonesta Boston on 3/30 and 3/31 in



2017 MassBio Annual Meeting

March 30, 2017 8:00 AM March 31, 2017 4:00 PM
Royal Sonesta Boston40 Edwin Land BoulevardCambridge MA US 02142


UPDATED on 3/2/2017

Governor Charlie Baker to Address MassBio’s Annual Meeting

MassBio is thrilled to announce that Governor Charlie Baker will address attendees of MassBio’s 2017 Annual Meeting, which focuses on the most critical challenges facing the Massachusetts life sciences industry. 

Check out some recent news stories on Governor Baker:  

We’re #1: US News & World Report Ranks Massachusetts Best State

CBS Boston, 2/28/2017

Massachusetts Puts $39 Million Behind STEM Education

CivSource, 2/22/2017

Baker backs immigrant visas for Mass. firms

The Boston Globe, 2/4/2017

Plenary Sessions

Value: Biotech in the Era of Real-World Evidence
It is a time of great change in healthcare, as patients seek insight and engagement in the development of treatments, policymakers disagree on whether to regulate the industry more or less, and the market shifts from volume-based to value-based payment models. With scientific discovery advancing faster than innovations to our insurance and payment models, how do biopharma companies plan for bringing new treatments to market?

We will discuss the trends toward convergence in drugs, diagnostics, devices and digital health

Cancer Moonshot: Where Des it Go From Here?

Better Business Track

The Next Generation
What are the challenges facing young researchers and new entrepreneurs today? We’ will discuss workforce development, diversity, the funding environment and more.

Changes in the Valley of Death
There is much hand-wringing over the challenges of getting early-stage funding today. But there has always been a “valley of death” in biotech. How is today’s valley different than in years past? Is it really harder to raise money today? How is the diverse and fragmented funding environment making the process harder or easier?

Emerging Markets in the Global Landscape
How are emerging markets and today’s global landscape impacting biopharma strategy?

Trends in Science Track

We will discuss current research and trends in Parkinson’s, Alzheimer’s, and other CNS diseases

CRISPR and What’s Next
A look at where CRISPR technology is heading and the next generation of gene editing tools (CAS9, Cpf1, etc.)

Pain & Addiction
We all understand the devastation that prescription drug addiction is causing in our society. But we can’t eliminate addiction until we discover a non-addictive method for treating pain. What’s next for pain?

As the population ages and lives longer, there is significant opportunity in research and treating diseases of aging. We will discuss osteoarthritis, hearing loss, Alzheimer’s, dementia and other health conditions related to aging.

Convergence Track (New for 2017!)

Funding Issues at the Intersections
Despite the hype about cross-industry collaboration and convergence, it is hard to raise money for technologies at the intersections of these industries. Who is funding convergent ideas and how do you sell them?

Big Data Analytics Possibilities

Next Generation Diagnostics

FDA Policy




Read Full Post »